Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HUTCHMED (China) ( (HK:0013) ) has shared an announcement.
HUTCHMED (China) Limited has scheduled a board meeting for March 5, 2026 to approve and release its audited financial results for the year ended December 31, 2025, with the announcement to be published that evening in Hong Kong. Following the results release, the company will hold separate English and Putonghua webcast presentations with Q&A for investors and analysts, underscoring its efforts to maintain active investor communication and transparency around its financial performance and strategic direction.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is a Cayman Islands–incorporated biopharmaceutical company listed in Hong Kong that focuses on the discovery, development and commercialization of innovative therapies, particularly oncology and immunology drugs, serving patients in China and global markets.
Average Trading Volume: 4,981,644
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$20.01B
See more data about 0013 stock on TipRanks’ Stock Analysis page.